Ipledgeprogram
ipledgeprogram.comRank Trend
Ranking history over time.
About Ipledgeprogram
The iPLEDGE Program REMS is a safety initiative designed to manage the risks associated with isotretinoin, particularly its potential teratogenic effects. This program is mandated by the U.S. Food and Drug Administration (FDA) to ensure that the benefits of isotretinoin outweigh its risks for patients.
Learn about the iPLEDGE Program and its safety measures for isotretinoin use.
What You Can Do
- Understand the risks of isotretinoin
- Access safety guidelines and requirements
- Find information on patient enrollment
Frequently Asked Questions
What is the iPLEDGE Program?
The iPLEDGE Program is a safety program required by the FDA to manage the risks associated with isotretinoin.
Why is isotretinoin considered risky?
Isotretinoin is associated with teratogenic effects, meaning it can cause birth defects if taken during pregnancy.
How can patients enroll in the iPLEDGE Program?
Patients can enroll in the iPLEDGE Program through their healthcare provider, who will guide them through the necessary steps.
What are the requirements for participating in the iPLEDGE Program?
Participants must comply with specific safety measures, including regular pregnancy tests and contraception requirements.
Is the iPLEDGE Program mandatory?
Yes, participation in the iPLEDGE Program is mandatory for patients prescribed isotretinoin.